Vascular Biogenics - VBLT Stock Forecast, Price & News

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Analysts Set New Price Targets

A number of equities research analysts have commented on VBLT shares. Oppenheimer cut shares of Vascular Biogenics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, July 20th. StockNews.com started coverage on shares of Vascular Biogenics in a research note on Saturday. They set a "sell" rating on the stock. Chardan Capital cut shares of Vascular Biogenics from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 20th. Jonestrading reiterated a "buy" rating and set a $5.00 price objective on shares of Vascular Biogenics in a research report on Friday, May 20th. Finally, HC Wainwright cut shares of Vascular Biogenics from a "buy" rating to a "neutral" rating in a research report on Wednesday, July 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $4.88.

Vascular Biogenics Stock Performance

Shares of Vascular Biogenics stock traded up $0.02 on Wednesday, hitting $0.26. 4,803,664 shares of the company traded hands, compared to its average volume of 1,258,668. The stock has a market capitalization of $17.89 million, a P/E ratio of -0.56 and a beta of 0.58. Vascular Biogenics has a 52 week low of $0.21 and a 52 week high of $2.54. The business has a 50-day simple moving average of $1.20 and a 200 day simple moving average of $1.39.

Vascular Biogenics (NASDAQ:VBLT - Get Rating) last released its quarterly earnings data on Tuesday, May 17th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Vascular Biogenics had a negative net margin of 4,894.40% and a negative return on equity of 69.21%. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.20 million. During the same quarter in the previous year, the business earned ($0.12) EPS. Research analysts expect that Vascular Biogenics will post -0.51 earnings per share for the current year.